Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
作者信息
Kai A C, Flohr C, Grattan C E
机构信息
Cutaneous Allergy, St John's Institute of Dermatology, St Thomas' Hospital, London, SE1 7EH, UK.
出版信息
Clin Exp Dermatol. 2014 Jul;39(5):651-2. doi: 10.1111/ced.12320. Epub 2014 Apr 23.
PMID:24758481
Abstract
摘要
Zotero 插件